Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Biophytis, de nieuwe raket?
Volgen
Weinig belangstelling hier, vandaag in ieder geval aan een mooie klim bezig. Zitten nu in fase 2/3 van hun geneesmiddel tegen de negatieve effecten van covid. Het is eens wat anders dan testers.
Vandaag opnieuw mooi groen, blijf nog even zitten.
Raar slot vandaag. Biophytis bij De Giro plotsklaps van 0,71 naar 0,667 in de naveiling. Morgen weer flink up. Kind regards, Forecast
Fout in de weergave van de koers gelukkig. Vandaag richtng 0,80 cent moet lukken. Kind regards, Forecast
Forecast2006 schreef op 3 november 2020 06:39 :
Fout in de weergave van de koers gelukkig.
Vandaag richtng 0,80 cent moet lukken.
Kind regards,
Forecast
Terug naar 60 cent zit dichter in de buurt.
Covid-19 Test fase2/3 gestart op 26 oktober ( duur 28 dagen ) uitslag verwacht eind november. Kind regards, Forecast
zo hebben we weer iets om naar uit te kijken :-)
Ik zit met een GAK van 0,75 Twijfel om rond de 0,6 in te kopen om het wat te verlagen Wat is er nog meer de verwachting naast de gestarte testfase 2/3? Is er meer nieuws?
precies ineens wat koopdruk, zou er nieuws zijn? Ik kan in ieder geval niks vinden...
we krijgen zelfs nog en freeze voor het afsluiten vandaag, merkwaardig
Heel apart dit, schiet omhoog...
Ben vorige week ingestapt in dit aandeel. Na een flinke lift en daarna een daling (GAK 0,72) hebben we gisteren wel een hele vreemde stijging gezien op het einde van de dag... Blijf voorlopig rustig zitten en hopen op mooi nieuws om het aandeel verder omhoog te stuwen
Weer 11% eraf. Is er nieuws?
[quote alias=Forecast2006 id=12875422 date=202011040753] Covid-19 Test fase2/3 gestart op 26 oktober ( duur 28 dagen ) uitslag verwacht eind november. Nog niks kunnen terug vinden op hun site, we stijgen echter wel vandaag...
Ze gaan als een speer vandaag, eigenaardig ik vind nog steeds geen nieuws op hun site?
Heb alles eruit gemieterd op 71.8 GAK was 75, maar zag dit als een eenmalige kans om het met een redelijk klein verlies te verkopen.. Blijft een waardeloos aandeel, geen nieuws, niks. Zal straks wel weer terugvallen naar 60 oid Mij niet meer gezien
Je had precies toch nog beter enkele dagen gewacht met verkopen...
Deze keer wel een stijging op nieuws, dit staat op de website: Biophytis - First Patient Enrolled in France in COVA, an International Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure First Patient Dosed at La Pitié-Salpêtrière University Hospital in Paris Total of eight centers authorized by French National Health Agency (ANSM) for patient recruitment in France Paris, (France), Cambridge (Massachusetts, United States), December 11, 2020, 8:00 a.m. CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that the first French patient has been dosed at La Pitié-Salpêtrière University Hospital, Paris, in COVA. The COVA study is a Phase 2/3 clinical trial with Sarconeos (BIO101) for the treatment of patients with COVID-19-related respiratory failure. Dr. Capucine Morelot-Panzini, Professor of Pulmonology at the Pitié-Salpêtrière University Hospital in Paris is the Principal Investigator of COVA in France. In addition to the two first centers at the Pitié-Salpêtrière University Hospital in Paris, Biophytis also received approval from the French National Agency for Medicines and Health Products Safety (ANSM) this month to open six new centers in France, among which Centre Hospitalier Rene Dubos and Centre Hospitalier d’Argenteuil in the Paris Region, bringing the total to eight centers planned to recruit COVID-19 patients in France. A total of 17 centers are now actively recruiting in Belgium, Brazil, France and the US among a targeted number of around thirty to be opened for the second part of the COVA study . The international COVA clinical program (clinicaltrials.gov identifier NCT04472728) is a global, multicentric, double-blind, placebo-controlled, group-sequential and adaptive two-part Phase 2-3 study assessing Sarconeos (BIO101) in patients aged 45 and older, infected with SARS-CoV2. This pivotal clinical trial is being conducted in two parts, the first of which will assess the treatment safety and provide an indication of activity of Sarconeos (BIO101) in 50 hospitalized patients. The study is designed to evaluate the efficacy and the safety of Sarconeos (BIO101) as a treatment to prevent further deterioration of patients with COVID-19-related respiratory failure, which could otherwise require admission to the intensive care units and ventilation. Press release The first part of the study is a Phase 2 exploratory proof of concept study to provide preliminary data on the activity, safety and tolerability of Sarconeos (BIO101) in 50 hospitalized patients with severe respiratory manifestations related to COVID-19. The second part of the study will investigate the safety and efficacy of Sarconeos (BIO101) on the respiratory function of 310 COVID-19 patients (including the 50 patients from Part 1 of the study). Interim analysis and completion of full trial enrollment is expected in Q1 2021. Stanislas Veillet, CEO of Biophytis says: “I am very pleased that after all of the efforts by our teams over the past few months, we can now announce the first patient has been dosed at La Pitié-Salpêtrière Hospital and start our COVA clinical program in France. We have been working for many years with the team at La Pitié-Salpêtrière Hospital, which is linked with Sorbonne University’s medical school, a long-standing partner of Biophytis. The continued surge of COVID19 cases in France, Europe and the Americas and subsequent hospitalizations, re-emphasizes the emergency of finding innovative treatments against the pandemic (even while a vaccine is being rolled-out). We project enrollment of the 50 patients required for the first part of the study to complete in the coming weeks. Topline results of the COVA trial are expected in Q2 2021.” *** About BIOPHYTIS Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARAINT). It is also being studied in a clinical two-part Phase 2/3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com Disclaimer This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by Press release a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website (www.biophytis.com). This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail. Biophytis Contact for Investor Relations Evelyne Nguyen, CFOevelyne.nguyen@biophytis.com Media contact Citigate Dewe Rogerson Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussartbiophytis@citigatedewerogerson.com Tel: +44 (0) 20 7638 9571 / +33 (0)1 55 30 70 91
Ondertussen zitten we al aan de derde freeze van de dag :-)
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
866,54
+0,14%
EUR/USD
1,0682
+0,10%
FTSE 100
7.878,75
+0,39%
Germany40^
17.809,50
+0,22%
Gold spot
2.379,33
+0,78%
NY-Nasdaq Composite
15.683,37
-1,15%
Stijgers
Dalers